Physician profile
Ryan Murphy
NPI 1134575012
$4,142.66
in general payments reported to CMS, 2019-2025
20 companies · $979 in 2025
The $979 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $90.09 · 2021: $471 · 2022: $316 · 2023: $262 · 2024: $1,915 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751 · Travel and Lodging: $1,306 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.77 |
| Travel and Lodging | $1,306.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,477.68 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 |
| Astrazeneca Pharmaceuticals LP | $286.76 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Pfizer INC. | $249.80 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $234.87 | 2021-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $185.00 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $115.79 | 2023-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.31 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $84.16 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.87 | 2021 | |
| Cvrx, INC. | $77.87 | 2025 | Barostim Neo System |
| Abiomed | $48.90 | 2022-2025 | |
| Amgen INC. | $37.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $27.93 | 2021-2022 | |
| Mannkind Corporation | $26.30 | 2025 | |
| Lantheus Medical Imaging, INC. | $25.02 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $22.82 | 2025 | Attruby |
| Philips North America LLC | $16.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.75 | 2023 | Camzyos |
| Merck Sharp & Dohme LLC | $14.85 | 2024 | Verquvo |
| Eisai INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.